Roche offers researchers access to all Tamiflu trials

  title={Roche offers researchers access to all Tamiflu trials},
  author={Deborah Cohen},
  journal={BMJ : British Medical Journal},
  • D. Cohen
  • Published 4 April 2013
  • Medicine
  • BMJ : British Medical Journal
More than three years after the Cochrane Collaboration first asked Roche for the full clinical study reports for its influenza drug oseltamivir (Tamiflu), the Swiss company has offered the collaboration access to “all 74 Roche sponsored trials.” Don MacLean, life cycle leader for Tamiflu at Roche, emailed the Cochrane researchers on 2 April to propose providing data in a staggered approach over the next few months. “In line with European Union law, each CSR [clinical study report] will be… 
Cochrane researchers continue to face challenges over access to data on flu drugs
Cochrane Collaboration researchers have said that they may be unable to analyse clinical trial data given to them by GlaxoSmithKline (GSK) on the antiviral drug zanamivir (marketed as Relenza)
Roche continues to drag its feet on access to Tamiflu data
Four years after it was first promised (but not fulfilled), Roche is again offering Cochrane researchers access to its trial reports on Tamiflu. But Roche is offering less than full transparency: “In
New expert group agrees plan to analyse full data on oseltamivir
A multidisciplinary group of scientific experts has developed a plan to analyse data on the influenza drug oseltamivir (Tamiflu) that they hope will provide answers to whether current guidelines on
Study claiming Tamiflu saved lives was based on “flawed” analysis
A study that found that neuraminidase inhibitors reduced the risk of death among adults treated in hospital during the 2009-10 H1N1 flu pandemic was based on a flawed analysis, a statistician has
Clinical Trial Transparency and Orphan Drug Development: Recent Trends in Data Sharing by the Pharmaceutical Industry
Major developments in clinical trial transparency between January and June 2013 are summarized and the composition of datasets released by GlaxoSmithKline are analyzed to find data currently listed is diverse and could be promising for researchers interested in rare disease treatment.
Use of Neuraminidase Inhibitors in Primary Health Care during Pandemic and Seasonal Influenza between 2009 and 2013
Although physicians seem to follow the recommended indications for NIs in primary health-care practice, this study confirms the low rate of NI prescription to ILI patients with a severe influenza risk factor, especially during seasonal epidemics.
The hi-tech detection of Darwin's and Wallace's possible science fraud:
Priority for discoveries is awarded to those who are first to publish. If a scholar writes claiming to have discovered something or originated a theory that has been earlier published, or presented


WHO and the pandemic flu “conspiracies”
Key scientists advising the World Health Organization on planning for an influenza pandemic had done paid work for pharmaceutical firms that stood to gain from the guidance they were preparing. These